{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Proteasome+Inhibitor&page=2", "query": { "intervention": "Proteasome Inhibitor", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 105, "total_pages": 11, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Proteasome+Inhibitor&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Proteasome+Inhibitor&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-02T03:24:10.186Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02757326", "title": "ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Opaganib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "RedHill Biopharma Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2016-12-13", "completion_date": "2019-05", "has_results": true, "last_update_posted_date": "2021-06-18", "last_synced_at": "2026-10-02T03:24:10.186Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02757326" }, { "nct_id": "NCT07705334", "title": "A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced or Metastatic Solid Tumors", "Triple Negative Breast Cancer (TNBC)", "HR+ Breast Cancer", "Colon Cancer", "Gastric Cancer", "Hepatecellular Carcinoma", "NSCLC (Advanced Non-small Cell Lung Cancer)", "Mesothelioma", "Pancreatic Carcinoma Metastatic", "Hormone Refractory Prostate Cancer", "Soft Tissue Sarcomas" ], "interventions": [ { "name": "SHY-ONC6", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SHY Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2026-06-24", "completion_date": "2028-05-15", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-10-02T03:24:10.186Z", "location_count": 4, "location_summary": "Scottsdale, Arizona • Denver, Colorado • Houston, Texas + 1 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07705334" }, { "nct_id": "NCT00028639", "title": "PS-341 in Treating Women With Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": null, "start_date": "2001-08", "completion_date": "2003-11", "has_results": false, "last_update_posted_date": "2011-07-29", "last_synced_at": "2026-10-02T03:24:10.186Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00028639" }, { "nct_id": "NCT02294357", "title": "Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2014-12", "completion_date": "2020-09-22", "has_results": false, "last_update_posted_date": "2023-11-01", "last_synced_at": "2026-10-02T03:24:10.186Z", "location_count": 7, "location_summary": "Encinitas, California • West Hills, California • West Hollywood, California + 4 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "West Hills", "state": "California" }, { "city": "West Hollywood", "state": "California" }, { "city": "Fleming Island", "state": "Florida" }, { "city": "Poughkeepsie", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02294357" }, { "nct_id": "NCT03201250", "title": "Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma", "Refractory Multiple Myeloma", "Relapsed/Refractory Multiple Myeloma" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 11, "start_date": "2018-02-21", "completion_date": "2021-04-12", "has_results": true, "last_update_posted_date": "2023-09-08", "last_synced_at": "2026-10-02T03:24:10.186Z", "location_count": 2, "location_summary": "Omaha, Nebraska • Houston, Texas", "locations": [ { "city": "Omaha", "state": "Nebraska" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03201250" }, { "nct_id": "NCT01832727", "title": "Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Oprozomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2013-07-02", "completion_date": "2019-06-25", "has_results": true, "last_update_posted_date": "2020-07-13", "last_synced_at": "2026-10-02T03:24:10.186Z", "location_count": 10, "location_summary": "Los Angeles, California • Tampa, Florida • Westwood, Kansas + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Westwood", "state": "Kansas" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01832727" }, { "nct_id": "NCT05730036", "title": "A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsed Refractory Multiple Myeloma (RRMM)" ], "interventions": [ { "name": "Linvoseltamab", "type": "DRUG" }, { "name": "Elotuzumab", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 410, "start_date": "2023-09-18", "completion_date": "2033-04-19", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-02T03:24:10.186Z", "location_count": 10, "location_summary": "Los Angeles, California • Gainesville, Florida • Lexington, Kentucky + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Stony Brook", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05730036" }, { "nct_id": "NCT00295932", "title": "Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "bortezomib", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 79, "start_date": "2005-12-13", "completion_date": "2018-03-11", "has_results": true, "last_update_posted_date": "2018-11-20", "last_synced_at": "2026-10-02T03:24:10.186Z", "location_count": 8, "location_summary": "Atlanta, Georgia • Basking Ridge, New Jersey • New Brunswick, New Jersey + 4 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00295932" }, { "nct_id": "NCT05020236", "title": "A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Elranatamab", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 893, "start_date": "2021-10-04", "completion_date": "2027-05-31", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-10-02T03:24:10.186Z", "location_count": 26, "location_summary": "Clovis, California • Fresno, California • Fort Collins, Colorado + 17 more", "locations": [ { "city": "Clovis", "state": "California" }, { "city": "Clovis", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Fort Collins", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05020236" }, { "nct_id": "NCT00512798", "title": "Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors", "Melanoma", "Solid Tumor" ], "interventions": [ { "name": "PS-341 (VELCADE)", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "immunoenzyme technique", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2003-06", "completion_date": "2008-03", "has_results": true, "last_update_posted_date": "2012-10-02", "last_synced_at": "2026-10-02T03:24:10.186Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00512798" } ] }